USDA Perspective on 3R Implementation

Geetha B. Srinivas, D.V.M., Ph.D.
Section Head, Virology & Molecular Biology
Policy, Evaluation, and Licensing
Center for Veterinary Biologics
USDA APHIS
Geetha.B.Srinivas@usda.gov



Objectives

- Regulatory framework
- 3R Enhancements: Manufacturer Initiated
- 3R Enhancements: CVB Initiated
 - International Collaborations
 - Agency Led Projects



Regulatory Framework

- Virus-Serum-Toxin Act (1913 & 1985)
 (21 U. S. Code, Sections 151-159)
- Title 9 Code of Federal Regulations (Parts 101-122)
- Veterinary Service Memoranda
- CVB Notices





Virus-Serum-Toxin Act

- Prohibits Worthless, Dangerous, Contaminated, or Harmful (W-D-C-H) biologics
- 3R initiatives
 - Must meet the standards of the VSTA



Outline of Production

- Critical Elements
 - Components of Biologics
 - Production Process
- Regulatory Flexibility-
 - Approved scientifically sound production changes allowed over time
- Final Product Testing
 - Foundation of market release



Final Product Testing

- Potency
 - In vivo
 - In vitro

- Safety
 - Target Animal Batch Safety
 - Laboratory Animal Batch Safety

Animal Safety Batch Testing ExemptionsInternational Collaboration

- Designed for Target Animal Safety
 - Target Animal Safety Tests
 - Laboratory Animal Safety Tests
- Does it still provide the same need?
- VICH Guidance





VICH Considerations

- Consistent, quality manufacturing processes as determined by a regulated authority
 - Seed lot manufacturing system
- Sufficient number of serials pass animal batch safety testing
- Pharmacovigilance Data



VICH Guidance

- VICH GL50: Harmonization of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use (2013)
- VICH GL55: Harmonization of criteria to waive target animal batch safety testing for live vaccines for veterinary use (2017)
- VICH GL59: Harmonization of criteria to waive laboratory animal batch safety testing for vaccines for veterinary use (2020)



VSM 800.116 Target Animal Safety Exemption

- Harmonize with VICH GL50 and GL55
- Evaluate final product testing results of 10 serials or 5 serials if 10 not manufactured in 3 years
- Evaluate manufacturing changes in Outline of Production
- Evaluate Pharmacovigilance data by firm submission of adverse event reports
- Exemption required license restriction to report adverse events



Draft Revision to Veterinary Services Memorandum 800.116

- Add laboratory animal batch safety exemption to harmonize with VICH GL59
- Pharmacovigilance data evaluated by CVB adverse event reporting system per Veterinary Services Memorandum 800.125
 - Effective February 27, 2021
 - Data available in CVB system
 - License restriction to report data not needed



3R Initiatives: Manufacturer Initiated

- Limited Use
 - Confidential Business Information
- Veterinary Biologics Manufacturer Groups
 - AHI (Animal Health Institute)
 - AVBC (Association of Veterinary Biologics Companies)

3R Initiatives: Manufacturer Initiated

- In vitro Potency Tests
 - VS Memorandum 800.112: Guidelines for Validation of *In Vitro* Potency Assays
 - Conceptualization
 - Development
 - Optimization
 - Verification
 - Monitoring
- Other enhancements
 - Reduction
 - Refinement
 - Analgesia

3R Initiatives: CVB Initiated

- Industry-wide advantage
- International Collaborations
- Independent Research

CVB Independent Research

- Information shared with industry
 - AHI, AVBC and other public meetings
 - Notices and Memorandums
 - Posting of testing methods on public website
- Reagents
 - Antibodies

 Leptospira, Clostridials, E. coli, etc
 - References
 Rabies
- Protocols and Supplemental Assay Methods
 - Publicly available through the CVB website


CVB Independent Research: Leptospira Regulatory Enhancements

- Replacement of codified hamster assays with ELISAs
 - Antibodies and References available
 - Product specific validation is required
- Exemption of back-titration hamsters from the codified assays
 - Notices 15-13 and 17-06
- Cryopreservation of virulent challenge



CVB Independent Research: Leptospira 3R Implementation

Hamsters Per Doses Released





CVB Independent Research: Cell Based Toxin-Antitoxin Assays

- Potency test for Clostridium septicum Alpha antitoxin using a Cell Assay
 - VERO Cells
 - https://www.aphis.usda.gov/animal_health/vet_biologics/publications/BBPRO1009.pdf
- Potency test for Clostridium perfringens
 Type D epsilon antitoxin using a Cell
 Assay
 - MDCK Cells
 - https://www.aphis.usda.gov/animal_health/vet_bi_ ologics/publications/BBPRO1008.pdf

Increasing amounts of toxin added to a standard and unknown antitoxin to determine the amount of antitoxin present by monitoring cell death

Conclusions

- Overview of CVB Regulatory Approach
- Manufacturer led 3R Initiatives
- International 3R Initiatives:
 - Animal Batch Safety Testing Exemptions
- CVB Independent Validation of 3R Initiatives
 - Reagents
 - Protocols
 - Memoranda and Notices



Animal and Plant Health Inspection Service

Veterinary Services

Center for Veterinary Biologics

1920 Dayton Avenue PO Box 844 Ames, IA USA 50010

Phone: (515) 337-6100

Email:

Geetha.B.Srinivas@usda.gov

